Medicilon won the "Science and Innovation Golden Horse Excellent Company Award " at the 2021 Science and Technology Leaders Summit

On July 22, 2019, the Shanghai Sci-Tech Innovation Board (STAR) opened.  Two years later, on July 22, 2021, 313 companies are listed on the STAR.  The monthly average number of listed companies is 13, which is 19.92% more than the main board of the same period and 36.09% more than the GEM. The scale of IPO funds raised is RMB 387.438 billion, with a total market value of RMB 4,878,435 million. (Sources: Securities Daily)

On September 27, 2021, the “2021 Science and Technology Leaders Summit“, guided by the China Association of Listed Companies, hosted by the Securities Daily, and undertaken by the Securities Daily Social Science Innovation Leaders Alliance, was held at the China Securities Museum.  With the theme of “Inheritance and Innovation”, the summit offered advice and suggestions on “How to seize the 14th Five-Year Opportunity and enhance core competitiveness”.  During the summit, the “Science and Innovation Golden Horse Award” was announced after months of competition.

As the first CRO to land on the STAR, Shanghai Medicilon Inc. (stock code: 688202.SH) (Medicilon) is driven by independent innovation of the R&D service platform to develop a new technology.  Embarking on a path of high-quality development driven by technological innovation, Medicilon was awarded the “Science and Innovation Golden Horse Excellent Company Award”, which demonstrate the high recognition of the value of Medicilon by the capital market.

It is reported that the selection of the “Science and Innovation Golden Horse Excellent Company Award” is extremely strict, and there are hard indicators for the company’s industry position, technological leadership and performance growth rate.  Strict selection has been carried out on multiple dimensions such as good economic and social benefits of the company’s technological innovation products, core competitiveness of the company’s technological innovation products and industry leadership, and the growth rate of operating income and net profit in the past three years.

This award means that the capital market has highly recognized and affirmed Medicilon’s leading position, innovative technology and business performance.  The influence of Medicilon’s capital market has been further enhanced!

In the future, Medicilon will continue to strictly abide by relevant regulatory rules based on the hot land of the sci-tech innovation board capital market, and further develop new drug research and development service platforms, expand and strengthen, and consolidate the new drug R&D, in order to improve the quality of life of all mankind.